While previous studies have identified the importance of Lyn in imatinib-resistant CML [21], [22], [69], our studies further identified dysregulation of two well characterized kinase pathways (MEK/ERK and IKK/NF-κB) and demonstrated their relationship to activation of Lyn. The gene discussed is LYN; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.